149 related articles for article (PubMed ID: 15123403)
1. Potential pathologic markers for prostate chemoprevention studies.
Sakr WA; Lucia MS
Urol Clin North Am; 2004 May; 31(2):227-35. PubMed ID: 15123403
[TBL] [Abstract][Full Text] [Related]
2. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
3. The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.
Bostwick DG; Burke HB; Wheeler TM; Chung LW; Bookstein R; Pretlow TG; Nagle RB; Montironi R; Lieber MM; Veltri RW
J Cell Biochem Suppl; 1994; 19():283-9. PubMed ID: 7529857
[TBL] [Abstract][Full Text] [Related]
4. Intermediate biomarkers for chemoprevention of prostate cancer.
van der Kwast TH
IARC Sci Publ; 2001; 154():199-205. PubMed ID: 11220659
[TBL] [Abstract][Full Text] [Related]
5. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
6. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
Marshall JR
IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
[TBL] [Abstract][Full Text] [Related]
7. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies.
Pathak SK; Sharma RA; Steward WP; Mellon JK; Griffiths TR; Gescher AJ
Eur J Cancer; 2005 Jan; 41(1):61-70. PubMed ID: 15617991
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention strategies for prostate cancer.
Bosland MC; McCormick DL; Melamed J; Walden PD; Zeleniuch-Jacquotte A; Lumey LH
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S18-27. PubMed ID: 12570331
[TBL] [Abstract][Full Text] [Related]
10. Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium.
Fleshner NE; Kapusta L; Donnelly B; Tanguay S; Chin J; Hersey K; Farley A; Jansz K; Siemens DR; Trpkov K; Lacombe L; Gleave M; Tu D; Parulekar WR
J Clin Oncol; 2011 Jun; 29(17):2386-90. PubMed ID: 21537051
[TBL] [Abstract][Full Text] [Related]
11. Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.
Marshall JR; Sakr W; Wood D; Berry D; Tangen C; Parker F; Thompson I; Lippman SM; Lieberman R; Alberts D; Jarrard D; Coltman C; Greenwald P; Minasian L; Crawford ED
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1479-84. PubMed ID: 16896036
[TBL] [Abstract][Full Text] [Related]
12. Finasteride for chemoprevention of prostate cancer: why has it not been embraced?
de Vere White RW
J Clin Oncol; 2007 Jul; 25(21):2999-3000. PubMed ID: 17634478
[No Abstract] [Full Text] [Related]
13. Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial.
Platz EA; Lippman SM
J Clin Oncol; 2009 Aug; 27(22):3569-72. PubMed ID: 19528369
[No Abstract] [Full Text] [Related]
14. Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion.
Man YG; Gardner WA
Med Hypotheses; 2008; 70(2):387-408. PubMed ID: 17658698
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of prostate cancer through dietary agents: progress and promise.
Syed DN; Khan N; Afaq F; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2193-203. PubMed ID: 18006906
[TBL] [Abstract][Full Text] [Related]
17. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
Tavora F; Epstein JI
Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
[TBL] [Abstract][Full Text] [Related]
18. Role of cell-free plasma DNA as a diagnostic marker for prostate cancer.
Allen D; Butt A; Cahill D; Wheeler M; Popert R; Swaminathan R
Ann N Y Acad Sci; 2004 Jun; 1022():76-80. PubMed ID: 15251943
[TBL] [Abstract][Full Text] [Related]
19. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer.
Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG
Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines.
Venkateswaran V; Fleshner NE; Klotz LH
Prostate Cancer Prostatic Dis; 2004; 7(1):54-6. PubMed ID: 14745439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
